RE: A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer

Source: JNCI - Category: Cancer & Oncology Authors: Tags: Correspondence Source Type: research